Categories

Business Ideas
Business Opportunities
Corporate
Home Business
International Business
Management
Online Business
Public Company
Public Relations
Small Business

Popular Articles

Sudoku puzzle
At the launch of Arvind Virmani’s book on Wednesday, Finance Minister Pranab Mukherjee said he was intrigued by the book’s title, The Sudoku of India’s Growth. He said he’d have thought that his chief economic advisor would not think India’s growth surge was a puzzle and that he would actually know what had driven the growth. Having got everyone laughing, Mukherjee said that though he had not read the book in any great detail, his interaction with Virmani had convinced him that though the growth may have puzzled many, Virmani actually had the key to the puzzle. Suman Bery of NCAER said meanwhile that the appropriate metaphor was not Sudoku but Rubik’s Cube.

Sweet 16 for Sensex: Time to rejig portfolio
On September 7, the Bombay Stock Exchange’s Sensitive Index, or Sensex, closed over 16,000 points for the first time in over a year. And the good news is that it has consistently been able to close above this mark.

News of the day

Crompton eyes overseas acquisition
Billionaire Gautam Thapar plans to buy companies to expand India’s third-largest equipment maker and add capacity in the nation’s biggest paper maker as demand in the world’s fastest growing major economy after China surges.
Management

Bharat Biotech gets patent for Lysostaphin

Hyderabad-based vaccines and biotherapeutics manufacturer Bharat Biotech International announced on Wednesday that its anti-staphylococcal molecule Lysostaphin had secured patent rights in US, Europe, China, Australia and other nations. - Opto Circuits" US arm signs multi-year supply contract with US firm - Vitamins, diabetic drugs to cost more - Abbott India Aug qtr net up 26% to Rs 22.21 cr - UAE drug firm gets nod for production of swine flu medicine - Bharat Biotech to test swine flu vaccine in 2 months - Glenmark Pharma raises Rs 413 cr through QIP Lysostaphin is a potent anti-staphylococcal therapeutic with a targeted specificity against staphylococcus aureus, which causes a range of diseases including wound infections, systemic and life-threatening conditions (endocarditis), osteomyelitis, pneumonia, brain abscesses, meningitis and bacteremia, food poisoning, scalded skin syndrome and toxic shock syndrome. Krishna Ella, chairman and managing director, said the patent rights for lysostaphin was a significant milestone in the company"s new therapeutic product development programme and would pave a way to develop products for regulated markets in addition to India. A pre-investigational new drug application meeting of the pre-clinical data has already been held with USFDA, he said. Lysostaphin is bactericidal and is indifferent to antibiotic resistance. "Lysostaphin could be a drug of choice for treating life threatening bacteremia,"" he said. The company so far has eight Indian and five international patents. Bharat Biotech is currently developing swine flu vaccine to combat H1N1 virus epidemic in India and other countries, according to a release.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009